

DUPILUMAB TREATMENT IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS IS EFFICACIOUS REGARDLESS OF AGE OF DISEASE ONSET: a Post Hoc Analysis of Two Phase 3 Clinical Trials

Jonathan I. Silverberg, Mark Boguniewicz, Jon Hanifin, Kim A. Papp, Haixin Zhang, Ana B. Rossi, Noah A. Levit

DUPILUMAB




Age of AD onset

The **age of onset for atopic dermatitis (AD)** can vary. However, little is known about possible differences in **treatment efficacy** by age of disease onset.

The SOLO 1 and 2 studies evaluated dupilumab efficacy and safety in adults with moderate-to-severe AD.

We examined efficacy of dupilumab vs placebo in 4 groups of adults with different reported **ages of AD onset**.



*p < 0.0001, **p < 0.05, dupilumab vs placebo

Signs



Eczema Area and Severity Index (EASI)




Investigator's Global Assessment (IGA)



Symptoms



Peak Pruritus Numerical Rating Score (NRS)



Quality of Life



Dermatology Life Quality Index (DLQI)



Itch, assessed by Peak Pruritus NRS, and quality of life, assessed by DLQI, also improved with dupilumab treatment in all 4 groups of adults analyzed.

Dupilumab showed similar significant improvement in **signs, symptoms, and QoL** regardless of **age of AD onset**.

PEER-REVIEWED
INFOGRAPHIC

Adis

OPEN
ACCESS

The infographic represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online.